Novel COVID-19 Disease: First coronavirus vaccine trial starts today | The Business Standard
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
SUNDAY, MAY 29, 2022
SUNDAY, MAY 29, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
First coronavirus vaccine trial starts today

Coronavirus chronicle

UNB/AP
16 March, 2020, 10:40 am
Last modified: 16 March, 2020, 01:42 pm

Related News

  • Pfizer says 3 Covid shots protect children under 5
  • WHO says no urgent need for mass monkeypox vaccinations
  • Covax calls for urgent action to close vaccine equity gap
  • Covax calls for urgent action to close vaccine equity gap
  • Indonesia to drop outdoor mask mandate as Covid-19 infections drop

First coronavirus vaccine trial starts today

Testing will begin with 45 young, healthy volunteers with different doses of shots co-developed by NIH and Moderna Inc

UNB/AP
16 March, 2020, 10:40 am
Last modified: 16 March, 2020, 01:42 pm
Employee Philipp Hoffmann, of German biopharmaceutical company CureVac, demonstrates research workflow on a vaccine for the coronavirus (COVID-19) disease at a laboratory in Tuebingen, Germany, March 12, 2020. Picture taken on March 12, 2020/ Reuters
Employee Philipp Hoffmann, of German biopharmaceutical company CureVac, demonstrates research workflow on a vaccine for the coronavirus (COVID-19) disease at a laboratory in Tuebingen, Germany, March 12, 2020. Picture taken on March 12, 2020/ Reuters

The first participant in a clinical trial for a vaccine to protect against the new coronavirus will receive an experimental dose today, according to a US government official.

The National Institutes of Health is funding the trial, which is taking place at the Kaiser Permanente Washington Health Research Institute in Seattle. The official who disclosed plans for the first participant spoke on condition of anonymity because the move has not been publicly announced.

Public health officials say it will take a year to 18 months to fully validate any potential vaccine.

Testing will begin with 45 young, healthy volunteers with different doses of shots co-developed by NIH and Moderna Inc. There's no chance participants could get infected from the shots, because they don't contain the virus itself. The goal is purely to check that the vaccines show no worrisome side effects, setting the stage for larger tests.

Dozens of research groups around the world are racing to create a vaccine as COVID-19 cases continue to grow. Importantly, they're pursuing different types of vaccines — shots developed from new technologies that not only are faster to produce than traditional inoculations but might prove more potent. Some researchers even aim for temporary vaccines, such as shots that might guard people's health a month or two at a time while longer-lasting protection is developed.

Also in the works: Inovio Pharmaceuticals aims to begin safety tests of its vaccine candidate next month in a few dozen volunteers at the University of Pennsylvania and a testing center in Kansas City, Missouri, followed by a similar study in China and South Korea.

Even if initial safety tests go well, "you're talking about a year to a year and a half" before any vaccine could be ready for widespread use, according to Dr Anthony Fauci, director of NIH's National Institute of Allergy and Infectious Diseases.

That still would be a record-setting pace. But manufacturers know the wait — required because it takes additional studies of thousands of people to tell if a vaccine truly protects and does no harm — is hard for a frightened public.

President Donald Trump has been pushing for swift action on a vaccine, saying in recent days that the work is "moving along very quickly" and he hopes to see a vaccine "relatively soon."

Today, there are no proven treatments. In China, scientists have been testing a combination of HIV drugs against the new coronavirus, as well as an experimental drug named remdesivir that was in development to fight Ebola. In the US, the University of Nebraska Medical Center also began testing remdesivir in some Americans who were found to have COVID-19 after being evacuated from a cruise ship in Japan.

For most people, the new coronavirus causes only mild or moderate symptoms, such as fever and cough. For some, especially older adults and people with existing health problems, it can cause more severe illness, including pneumonia. The worldwide outbreak has sickened more than 156,000 people and left more than 5,800 dead. The death toll in the United States is more than 50, while infections neared 3,000 across 49 states and the District of Columbia.

The vast majority of people recover. According to the World Health Organization, people with mild illness recover in about two weeks, while those with more severe illness may take three weeks to six weeks to recover.

World+Biz / Top News

Coronavirus / Coronavirus impact / Coronavirus challange / Corona virus vaccine / Vaccine / Coronavirus Vaccine / Vaccine trail

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Central bankers’ refusal to embark into ‘hard helicopter money’ experiment have been a good idea. Photo: Reuters
    Interbank exchange rate for dollar set at Tk89
  • A Regio regional passenger train operated by Deutsche Bahn AG travels on a bridge in Berlin. Photographer: Krisztian Bocsi/Bloomberg
    Why Germany is offering a summer of cheap trains
  • Patients opting to delay crucial treatment amid rising costs
    Patients opting to delay crucial treatment amid rising costs

MOST VIEWED

  • A woman wearing a face mask crosses a road at the Central Business District (CBD), amid the coronavirus disease (Covid-19) outbreak in Beijing, China May 10, 2022. REUTERS/Carlos Garcia Rawlins
    Shanghai to lift 'unreasonable' curbs on firms, Beijing eases restrictions
  • Photo: Collected
    US doctors reconsider Pfizer's Paxlovid for lower-risk Covid patients
  • People wearing protective face masks walk on a street, following new cases of the coronavirus disease (Covid-19), in Shanghai, China August 25, 2021. REUTERS/Aly Song
    'Tomorrow will be better': Shanghai inches towards Covid re-opening
  • North Korea says new fever cases under 100,000 as virus fight heats up
    North Korea says new fever cases under 100,000 as virus fight heats up
  • People in protective suits cross a street during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 26, 2022. REUTERS/Aly Song
    Shanghai heading out of lockdown but China still lost in economic gloom
  • A woman wearing a face mask crosses a road at the Central Business District (CBD), amid the coronavirus disease (Covid-19) outbreak in Beijing, China May 10, 2022. REUTERS/Carlos Garcia Rawlins
    Tightening Covid net, Beijing deals out punishments, stark warnings

Related News

  • Pfizer says 3 Covid shots protect children under 5
  • WHO says no urgent need for mass monkeypox vaccinations
  • Covax calls for urgent action to close vaccine equity gap
  • Covax calls for urgent action to close vaccine equity gap
  • Indonesia to drop outdoor mask mandate as Covid-19 infections drop

Features

Central bankers’ refusal to embark into ‘hard helicopter money’ experiment have been a good idea. Photo: Reuters

Venice has a 400-year-old Covid monetary lesson

2h | Panorama
Aiman R Khan. Illustration: TBS

Why ‘marry your rapist’ court orders are not always what they seem

5h | Thoughts
Photo: Collected

Top 3 The Ordinary products that give extraordinary results

7h | Mode
Photo: Courtesy

KVN Beauty: Channel your inner Bangalee baddie

7h | Mode

More Videos from TBS

Paper industry worth thousands of crores in Bogura

Paper industry worth thousands of crores in Bogura

1h | Videos
Photo: TBS

Tips to help you become a successful lawyer

8h | Videos
People bid adieu to Abdul Gaffar Chowdhury

People bid adieu to Abdul Gaffar Chowdhury

8h | Videos
Photo: TBS

Harassment over 'indecent clothing': Women gather at Narsingdi railway station to protest, show solidarity

8h | Videos

Most Read

1
Bangladesh Bank GM, DGM’s designation changed
Banking

Bangladesh Bank GM, DGM’s designation changed

2
Corporates go cashless…tax cut on cards
NBR

Corporates go cashless…tax cut on cards

3
Photo: Courtesy
Panorama

Misfit Technologies: A Singaporean startup rooted firmly in Bangladesh

4
British International Investment (BII) CEO Nick O’Donohoe. Illustration: TBS
Economy

BII to invest $450m in Bangladesh in 5 years

5
Representational image. Picture: Pixabay
Economy

Govt raises regulatory duty to discourage imports of 130 products

6
Photo: Collected
Industry

Spanish recycled cotton producer opens new facility in Bangladesh

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab